MediciNova, Inc.

NASDAQ:MNOV

Biotechnology

Healthcare
$1.33 -1.32%

-$0.02 today

Market cap
$68.14M
Beta
0.62
P/E (TTM)
-5.6
EPS (TTM)
-$0.24
52W Low $1.17High $1.96

Volume 0.12M

Average 0.04M

MNOV Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

MediciNova, Inc.NASDAQ: MNOV

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $735.18K (cash outflow) fell 9.6% year over year, behind the +256.3% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Accounts payables amounted to 112.3% of revenue in FY2025.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -9.6% toward the trailing-twelve-month pace of +256.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$735.18K-226.2% QoQ
Last fiscal yearDec 2025
$459.87K+247.2% YoY
LTMMar 2026
$537.67K+256.3% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.6%——
1 year+247.2%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
459.87K USD
Year-over-year change
+247.2%

Accounts Payables vs competitors

How MNOV compares with its peers on the latest reported figures

  • MNOV's LTM Mar 2026 accounts payables of $537.67K is the 10th largest of the 11 companies compared; the peer median is $902K.
  • Its year-over-year change of +256.3% is the 3rd highest of 11, against a peer median of -127.8%.
  • Accounts payables amounts to 90.1% of revenue for MNOV, versus a peer median of 32.0%.
MNOV Competitors Peer median
Accounts Payables for MNOV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$37.42M +505.9%—56.6%
VXRTVaxart, Inc.LTM Mar 2026$7.56M -40.6%+244.8%3.0%
IMUXImmunic, Inc.LTM Mar 2026$4.41M +702.6%+15.7%—
BMEABiomea Fusion, Inc.LTM Mar 2026$3.1M -201.8%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.52M -185.2%—27.6%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$2.48M -265.2%——
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$2.07M +152.7%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$1.96M -171.6%+106.5%—
CBUSCibus, Inc.LTM Mar 2026$1.56M -1070.8%—36.5%
MNOVMediciNova, Inc.LTM Mar 2026$537.67K +256.3%+11.8%90.1%
XBITXBiotech Inc.LTM Mar 2026$241K -83.9%——
Peer median (excluding MNOV) $902K-127.8%+106.5%32.0%

Competitors are the stored peer set for MNOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.13M)(14.07M)(8.57M)(11.05M)(12M)
Depreciation & Amortization26.15K17.71K20.3K21.08K20.1K
Deferred Income Tax00000
Stock-Based Compensation1.72M642.52K710.71K1.19M829.1K
Change in Working Capital(1.21M)334.1K111.99K(979.56K)1.17M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.03M)329.01K19.24K(312.35K)459.87K
Other Working Capital(181.42K)5.09K92.75K(667.21K)705.15K
Other Non-Cash Items216.93K163.19K297.49K173.32K173.68K
Operating Cash Flow(9.38M)(12.91M)(7.43M)(10.64M)(9.81M)
Capital Expenditures(28.73K)(5.01K)(21.3K)(895)0
Acquisitions (Net)05.01M000
Purchases of Investments0(59.88M)000
Sales of Investments019.88M39.93M00
Other Investing Activities0(5.01M)0198(2.9K)
Investing Cash Flow(28.73K)(40.01M)39.91M(697)(2.9K)
Debt Repayment00000
Common Stock Issued20.89M7.92K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(112.26K)000244.02K
Financing Cash Flow20.78M7.92K00244.02K
Effect of Forex Changes26.55K(16.81K)17.27K3.96K15.68K
Net Change in Cash11.39M(52.93M)32.49M(10.64M)(9.55M)
Free Cash Flow(9.41M)(12.92M)(7.45M)(10.64M)(9.81M)

MediciNova, Inc.

NASDAQ:MNOV

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.